Dublin, 15 July 2020 (GLOBE NEWSWIRE) – The “Contact Dermatitis (CD) – Epidemiology Forecast-2030” a report was added to ResearchAndMarkets.com offerings.

This report provides an in-depth understanding of the disease, the epidemiology of historical and predicted Contact Dermatitis (CD) in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Epidemiological perspective

The epidemiology of the diseases covered in this report provides historical epidemiology and estimates segmented by Diagnosed Total Contact Dermatitis, Specific Prevalent Contact Dermatitis Population Based on Clinical and Biological Evolution, Specific Gender Diagnosis, Prevalent Dermatitis Contact Population, Specific Prevalent Contact Dermatitis Population Based on Clinical and Biological Evolution, Specific Gender Diagnosis, Prevalent Dermatitis Contact Population, Specific Prevalent Contact Dermatitis Population Specific Contact Dermatitis and Prevalent Contact Dermatitis Specific age-specific diagnosis in the 7MM market that includes the United States, EU5 countries (Germany, France, Italy, Spain and the United Kingdom) and Japan from 2017 to 2030.

Epidemiology Segmentation

  • The total CD population diagnosed in 7 major markets was 43,359,201 in 2017.
  • In the case of CD in the United States, a prevalent diagnosed case was found to be 13,786,942 in 2017.
  • It was found that in the United States the number of ICD and ACD cases was 11,029,554 and 2,757,388 in 2017, respectively.
  • In addition, the number of cases of acute, sub-acute and chronic types of CD were 7,611,771, 2,903,530 and 3,271,641 in 2017 in the United States, respectively.
  • US gender specific data shows that the number of CD cases in men and women were 4,825,430 and 8,961,513 in 2017.
  • Age-specific data for CDs show that in the United States the maximum number of CD cases was found in the age group 46-60 with 4,411,822 cases in 2017, while the lowest number of cases was found in the age group 75+ with 275,739 cases in 2017.
  • In EU5 countries, the prevalence of diagnosed CD was found to be maximum in Germany with 6,645,210 cases, followed by France with 5,481,080 cases in 2017. Meanwhile, the fewest number of cases were found in Spain, with 1,982,709 cases in 2017.
  • In Japan, the prevalence of diagnosed CDs was found to be 5,107,575 in 2017.

Report Scope

  • This report includes a descriptive description of Contact Dermatitis (CD), explaining the causes, signs and symptoms, pathophysiology.
  • This report provides insight into the historical 7MM patient pool and is estimated to include the United States, EU5 countries (Germany, France, Italy, Spain and the United Kingdom) and Japan.
  • This report assesses the risk and burden of disease and highlights the unmet needs of Contact Dermatitis (CD).
  • This report provides disease epidemiological segmentation for 7MM by the Total Doses of the Diagnosed Contact Dermatitis Population (CD) and the Prevalent Population of Contact Dermatitis (CD) Diagnosed by Severity.

Report a Highlight

  • Eleven Years Forecast of Contact Dermatitis (CD)
  • 7MM Coverage
  • Prevalent Population of Total Diagnosed Contact Dermatitis (CD)
  • The publisher has analyzed type-based data for Contact Dermatitis (CD). Contact dermatitis can be of two types based on this data, namely, irritant contact dermatitis (ICD) and allergic contact dermatitis (ACD).
  • Specific data types based on clinical and biological evolution of Contact Dermatitis (CD) have also been analyzed by the publisher. On this basis, Contact Dermatitis can be divided into Acute, Sub-acute and Chronic types.
  • In addition, the publisher also analyzes gender specific data for Contact Dermatitis (CD), which clearly shows that CDs are more common among women than men.
  • This report also covers other major segments, namely, Population Specific Contact Dermatitis Contact Specific Contact Dermatitis (CD) diagnosed with age, where various age groups have been considered, such as 0-17, 18-29, 30-45, 46-60, 61 -75 and 75+. It has been found that CD affects patients who are 40 years or older.
  • The expected potential launch of therapy, EB01 (Edesa Biotech), could increase market size in the coming years, helped by an increase in the population diagnosed as Contact Dermatitis (CD).
  • The current treatment of Contact Dermatitis (CD) is mainly dominated by the use of off-label therapy, which includes Topical Corticosteroids (Clobetasol and Triamcinolone) and Emollients, Topical Immunosuppressants (Pimecromilus and Tacrolimus), Systemic Immunosuppressants (Antihistamine and others). (Antiseptics, Topical Antibiotics, Phototherapy and Other Immunosuppressants).

Main Topics Covered

1 Key Insights

Contact dermatitis at a glance

3 Executive Summary of Contact Dermatitis (CD)

4 Background and description of disease: contact dermatitis (CD)
4.1 Types
4.1.1 Irritant Contact Dermatitis (ICD)
4.1.2 Allergic Contact Dermatitis (ACD)
4.1.3 Contact Urticaria
4.2 Causes
4.2.1 Metals
4.2.2 Fragrances
4.2.3 Antibacterial Ointment
4.2.4 Formaldehyde
4.2.5 Isothiazolinones
4.2.6 Cocamidopropyl Betaine
4.2.7 Paraphenylene-Diamine
4.3 Symptoms
4.4 Pathophysiology
4.5 Diagnosis

5 Algorithms for CD Diagnosis and Management

6 Diagnostic Guidelines by the American Academy of Allergy Asthma & Immunology (AAAAI)
6.1 Clinical Evaluation
6.2 Paste testing recommendations
6.3 Clinically relevant sources of allergen exposure
6.4 CD of topical medication
6.5 Special population
6.5.1 CDs in children
6.5.2 Work CD

7 Diagnostic Guidelines by the British Association of Dermatologists (BAD)
7.1 Assessment and Investigation
7.2 Diagnostic Test (Diagnosis)
7.2.1 Patient preparation
7.2.2 Patch test
7.2.3 Time for patch test reading
7.2.4 Reading and the relevance of positive reactions
7.2.5 Photopatch Testing
7.2.6 Testing of open patches

8 Epidemiology and Population of Patients: Key Findings
8.1 7MM 7MM Total Dose Population Diagnosed Contact Dermatitis Diagnosed

9 Country Wise-Epidemiology of Contact Dermatitis
9.1 United States
9.1.1 Assumptions and Rationale
9.1.2 Total Prevalent Population of Contact Dermatitis Diagnosed in the United States
9.1.3 Specific Contact Dermatitis Population Specific-Diagnosed Based on Clinical and Biological Evolution in the United States
9.1.4 Population of Contact Dermatitis Contact Dermatitis Specific gender diagnosed specifically in the United States
9.1.5 Prevalent Population of Specific Contact Dermatitis that is age-specific diagnosed in the United States
9.1.6 Population of Contact Dermatitis Specific Contact Dermatitis specifically diagnosed in the United States
9.2 EU countries5
9.3 Germany
9.4 France
9.5 Italy
9.6 Spain
9.7 United Kingdom
9.8 Japan

For more information about visiting this report https://www.researchandmarkets.com/r/amnork

Research and Markets also offer Custom Research services that provide focused, comprehensive and designed research.

CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900


image source

to request modification Contact us at Here or [email protected]